Rational development of Stafib-2: a selective, nanomolar inhibitor of the transcription factor STAT5b
Abstract The transcription factor STAT5b is a target for tumour therapy. We recently reported catechol bisphosphate and derivatives such as Stafib-1 as the first selective inhibitors of the STAT5b SH2 domain. Here, we demonstrate STAT5b binding of catechol bisphosphate by solid-state nuclear magneti...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2017-04-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-017-00920-3 |